Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced a conference call and webcast scheduled for August 6, 2024, at 4:30 pm ET (1:30 pm PT). The event will provide a business update and report second quarter 2024 financial results. Interested parties can access the call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international), or by using a provided link for instant telephone access. A live webcast will be available through the investor relations section of Corvus' website, with a replay accessible for 90 days post-event.

News Market Reaction – CRVS

-2.65%

-2.65% Session move

In the trading session that priced this news, CRVS declined 2.65%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

When will Corvus Pharmaceuticals (CRVS) report its Q2 2024 financial results?

Corvus Pharmaceuticals (CRVS) will report its Q2 2024 financial results on August 6, 2024, during a conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT.

How can investors access Corvus Pharmaceuticals' (CRVS) Q2 2024 earnings call?

Investors can access Corvus Pharmaceuticals' (CRVS) Q2 2024 earnings call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international), or by using a provided link for instant telephone access. A live webcast will also be available through the company's investor relations website.

Will there be a replay available for Corvus Pharmaceuticals' (CRVS) Q2 2024 earnings webcast?

Yes, a replay of Corvus Pharmaceuticals' (CRVS) Q2 2024 earnings webcast will be available on the company's website for 90 days following the live event.